Sugi Predict

Sugi Predict / Compounds / SCHEMBL790905

SCHEMBL790905

SCHEMBL790905

CCn1cc(B2OC(C)(C)C(C)(C)O2)cn1

nearest known ligand 0.65

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 1/20 0.65
▸ LPL P06858 11/20 0.42
▸ LIPG Q9Y5X9 11/20 0.42
▸ IRAK4 Q9NWZ3 1/20 0.35
▸ KMT2A Q03164 1/20 0.34
▸ F11 P03951 1/20 0.34
▸ DGAT1 O75907 2/20 0.32
▸ GSK3A P49840 1/20 0.32
▸ GSK3B P49841 1/20 0.32
▸ PDK2 Q15119 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1331340 0.86 FFAR1 (0.61) FFAR1LPLLIPGIRAK4F11
SCHEMBL15679701 0.84 FFAR1 (0.63) FFAR1LPLLIPGIRAK4F11
SCHEMBL31262731 0.84 FFAR1 (0.63) FFAR1LPLLIPGIRAK4F11
SCHEMBL17247560 0.83 FFAR1 (0.58) FFAR1LPLLIPGIRAK4F11
SCHEMBL15661307 0.83 LIPG (0.51) FFAR1LPLLIPGF11DGAT1
SCHEMBL9280646 0.83 FFAR1 (0.61) FFAR1LPLLIPGIRAK4F11
SCHEMBL24609489 0.82 FFAR1 (0.57) FFAR1LPLLIPGIRAK4F11
SCHEMBL15882163 0.81 FFAR1 (0.60) FFAR1LPLLIPGIRAK4F11
SCHEMBL21275456 0.81 FFAR1 (0.60) FFAR1LPLLIPGIRAK4F11
SCHEMBL13157050 0.81 FFAR1 (0.60) FFAR1LPLLIPGIRAK4F11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 810 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4743081-A1 MODULATORS OF MITOCHONDRIAL DNA REPLICATION Pretzel Therapeutics, Inc. (US) 2026-05-20 — — EP disclosed
EP-3723754-B1 IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES MERCK SHARP & DOHME LLC (US) 2026-05-13 — — EP disclosed
EP-4735114-A1 SUBSTITUTED THIENO [3,2-B]PYRIDINES AS INHIBITORS OF PROTEIN KINASES Masarykova Univerzita (CZ) 2026-05-06 — — EP disclosed
EP-4737443-A1 SALT-INDUCIBLE KINASE INHIBITORY COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Tanabe Pharma Corporation (JP) 2026-05-06 — — EP disclosed
EP-4724431-A1 BENZOFURAN DERIVATIVES AS SIK INHIBITORS AND USE THEREOF Beone Medicines I GmbH (CH) 2026-04-15 — — EP disclosed
US-12600719-B2 Salt inducible kinase inhibitors THE GENERAL HOSPITAL CORPORATION (US) 2026-04-14 — — US disclosed
EP-3768675-B1 NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORP (KR) 2026-04-01 — — EP disclosed
US-20260085053-A1 BENZOFURAN DERIVATIVES AS SIK INHIBITORS AND THE USE THEREOF BEONE MEDICINES I GMBH (CH) 2026-03-26 — — US disclosed
US-20260062387-A1 SALT-INDUCIBLE KINASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME MITSUBISHI TANABE PHARMA CORPORATION (JP) 2026-03-05 — — US disclosed
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 — — US disclosed
WO-2008051805-A2 TRIAZOLO-PYRIDAZINE PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-05-02 — — WO disclosed
WO-2008018639-A2 GLYCINE TRANSPORTER INHIBITOR TAISHO PHARMACEUTICAL CO., LTD. (JP) 2008-02-14 — — WO disclosed
WO-2008018639-A2 GLYCINE TRANSPORTER INHIBITOR TAISHO PHARMACEUTICAL CO., LTD. (JP) 2008-02-14 — — WO disclosed
WO-2008001076-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2008-01-03 — — WO disclosed
US-20070275968-A1 Substituted Biphenyl Derivative SANKYO COMPANY, LIMITED (JP) 2007-11-29 — — US disclosed
EP-1798229-A1 SUBSTITUTED BIPHENYL DERIVATIVE Sankyo Company, Limited (JP) 2007-06-20 — — EP disclosed
US-20070082900-A1 Methods for inhibiting protein kinases SCHERING CORPORATION 2007-04-12 — — US disclosed
US-20070082900-A1 Methods for inhibiting protein kinases SCHERING CORPORATION 2007-04-12 — — US disclosed
US-20070072881-A1 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors SCHERING CORPORATION 2007-03-29 — — US disclosed
US-20070072881-A1 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors SCHERING CORPORATION 2007-03-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062387-A1 SALT-INDUCIBLE KINASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME SIK1, SIK3, SIK2 FFAR1 2539/4885LPL 3777/4885LIPG 2981/4885
US-20260085053-A1 BENZOFURAN DERIVATIVES AS SIK INHIBITORS AND THE USE THEREOF SIK1, CHUK, SIK2 FFAR1 1410/4885LPL 4140/4885LIPG 3802/4885
US-12600719-B2 Salt inducible kinase inhibitors GRK6, SGK1, CSNK1A1 FFAR1 1952/4885LPL 3079/4885LIPG 2394/4885
US-20070082900-A1 Methods for inhibiting protein kinases PIM1, AURKC, PIM3 FFAR1 4804/4885LPL 4030/4885LIPG 3302/4885
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB FFAR1 3516/4885LPL 263/4885LIPG 511/4885
US-20070275968-A1 Substituted Biphenyl Derivative COL2A1, COL1A1, FGFR3 FFAR1 1128/4885LPL 1800/4885LIPG 3612/4885
US-20070072881-A1 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors CDK2, CDK1, CDKN1A FFAR1 4610/4885LPL 3341/4885LIPG 3343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.